Skip to content
value.today

Atterocor, Inc.

🇺🇸 Ann Arbor, Michigan, USABiotechnologyFounded 2012
Total raised
$56 M
2 rounds on record
Latest round
$48 M
Dec 2015
First round on record
Jul 2012
Today
Private
No later event on record

Funding rounds

2 counted as startup funding, 1 other private sales on record. Open the number of investors for the round's details.

Funding rounds of Atterocor, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Dec 2017$50 MIssued in a merger or acquisition$50 to $250 million

Atterocor, Inc.: Private sale, Dec 2017

Investors in this round

14 investors had bought by the notice of Dec 28, 2017: 6 accredited, 8 not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$50 M of $59 M offered; $9 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Christopher Seiter · Executive Officer
  • Jeffery Brinza · Executive Officer
  • Julia Owens · Executive Officer, Director
  • Pharis Mohideen · Executive Officer
  • Carol Gallagher · Director
  • Carole Neuchterlein · Director
  • James Hindman · Director
  • James Topper · Director
  • Mary Lynne Hedley · Director
  • Randall Whitcomb · Director
  • Thierry Abribat · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On a merger: “This offering is being made in connection with a share exchange pursuant to which Millendo Therapeutics, Inc. acquired substantially all of the outstanding stock of Alize Pharma SAS.”

Signed by Julia Owens, President and Chief Executive Officer. Source: SEC Form D, newest notice filed Dec 28, 2017. Read the notice at the SEC.

equity, optionsSEC
Dec 2015$48 MNo. 2$10 to $50 million

Atterocor, Inc.: Raise no. 2, Dec 2015

Investors in this round

21 investors had bought by the notice of Jan 4, 2016: 21 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$48 M of $71 M offered; $23 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$500,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Julia C. Owens · Executive Officer, Director
  • Carol C. Gallagher · Director
  • James C. Topper · Director
  • Randall C. Whitcomb · Director
  • William C. Harrington · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Leerink Partners LLC (CRD 39011) · Boston, MassachusettsSold in CA, MA, NY

Signed by Julia C. Owens, President and Chief Executive Officer. Source: SEC Form D, newest notice filed Jan 4, 2016. Read the notice at the SEC.

equitySEC
Jul 2012$9 MNo. 1$2 to $10 million

Atterocor, Inc.: Raise no. 1, Jul 2012

Investors in this round

7 investors had bought by the notice of Feb 26, 2013: 7 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$9 M of $17 M offered; $8 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Julia C. Owens · Executive Officer, Director
  • Carol J. Gallagher · Director
  • James C. Topper · Director
  • Randall C. Whitcomb · Director
  • William J. Harrington · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Julia C. Owens, President and Chief Executive Officer. Source: SEC Form D and 2 amendments, newest notice filed Feb 26, 2013. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Atterocor, Inc. chose not to state its revenue in its newest notice of a funding round (Dec 2017).

    SEC Form D · Dec 2017

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Dec 2017

That is all the official record says: Atterocor, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Atterocor, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 21 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Atterocor, Inc.
NameRoleNamed in
Christopher SeiterExecutive officerDec 2017
Jeffery BrinzaExecutive officerDec 2017
Julia OwensExecutive officerDec 2017
Pharis MohideenExecutive officerDec 2017
Julia C. OwensExecutive officerJan 2016
Raili C. KerppolaExecutive officerSep 2012
Carol GallagherDirectorDec 2017
Carole NeuchterleinDirectorDec 2017
James HindmanDirectorDec 2017
James TopperDirectorDec 2017
Julia OwensDirectorDec 2017
Mary Lynne HedleyDirectorDec 2017
Randall WhitcombDirectorDec 2017
Thierry AbribatDirectorDec 2017
Carol C. GallagherDirectorJan 2016
James C. TopperDirectorJan 2016
Julia C. OwensDirectorJan 2016
Randall C. WhitcombDirectorJan 2016
William C. HarringtonDirectorJan 2016
Carol J. GallagherDirectorFeb 2013
William J. HarringtonDirectorFeb 2013
Andrew J. SchwabDirectorSep 2012